Sumitomo Mitsui Trust Group Reduces Stake in Amgen

The institutional investor lowered its position in the biotech company by 2.6% during the fourth quarter.

Apr. 12, 2026 at 10:53am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, industrial-looking financial machinery and equipment, conveying the complex nature of institutional investing in the biotech sector.Institutional investors carefully adjust their positions in biotech giants like Amgen, reflecting broader market trends.Thousand Oaks Today

Sumitomo Mitsui Trust Group Inc. lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,612,368 shares of the medical research company's stock after selling 43,704 shares.

Why it matters

Sumitomo Mitsui Trust Group is a major institutional investor, and changes in its holdings can provide insights into market trends and investor sentiment around Amgen's stock. The reduction in stake, though relatively small, could signal a shift in the firm's outlook on the biotech company.

The details

According to the 13F filing, Sumitomo Mitsui Trust Group owned 0.30% of Amgen, valued at $527,744,000 at the end of the fourth quarter. The firm sold 43,704 shares during the period, lowering its total position in the company.

  • Sumitomo Mitsui Trust Group filed its 13F report for the fourth quarter of 2025.

The players

Sumitomo Mitsui Trust Group Inc.

A major Japanese financial services group and institutional investor.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Sumitomo Mitsui Trust Group's Amgen stake, though modest, could signal a shift in investor sentiment around the biotech company. As a major institutional investor, the firm's portfolio changes are worth monitoring for insights into broader market trends.